0.06
+0.0021(+3.89%)
Currency In USD
| Previous Close | 0.05 |
| Open | 0.05 |
| Day High | 0.06 |
| Day Low | 0.05 |
| 52-Week High | 12.8 |
| 52-Week Low | 0.05 |
| Volume | 26.23M |
| Average Volume | 72.61M |
| Market Cap | 8.43M |
| PE | -0.05 |
| EPS | -1.19 |
| Moving Average 50 Days | 0.13 |
| Moving Average 200 Days | 0.64 |
| Change | 0 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $5.65 as of December 21, 2024 at a share price of $0.056. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 2 years ago, it would be worth $5.47 as of December 21, 2024 at a share price of $0.056.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
GlobeNewswire Inc.
Dec 06, 2024 2:00 PM GMT
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with ph
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
GlobeNewswire Inc.
Nov 15, 2024 1:45 PM GMT
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with pha
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
GlobeNewswire Inc.
Nov 11, 2024 1:15 PM GMT
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next